EP2139470A4 - Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés - Google Patents
Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associésInfo
- Publication number
- EP2139470A4 EP2139470A4 EP08732593A EP08732593A EP2139470A4 EP 2139470 A4 EP2139470 A4 EP 2139470A4 EP 08732593 A EP08732593 A EP 08732593A EP 08732593 A EP08732593 A EP 08732593A EP 2139470 A4 EP2139470 A4 EP 2139470A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticular
- methods
- gamma radiation
- making same
- radiation sterilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89664707P | 2007-03-23 | 2007-03-23 | |
| PCT/US2008/057701 WO2008118754A2 (fr) | 2007-03-23 | 2008-03-20 | Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2139470A2 EP2139470A2 (fr) | 2010-01-06 |
| EP2139470A4 true EP2139470A4 (fr) | 2010-07-28 |
Family
ID=39789241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08732593A Withdrawn EP2139470A4 (fr) | 2007-03-23 | 2008-03-20 | Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2139470A4 (fr) |
| JP (1) | JP2010522207A (fr) |
| CA (1) | CA2680106A1 (fr) |
| WO (1) | WO2008118754A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008291930B2 (en) * | 2007-08-24 | 2014-04-17 | Slotervaart Participaties Bv | Compositions for the treatment of neoplastic diseases |
| US9089544B2 (en) | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| CA2763456C (fr) * | 2009-05-27 | 2017-10-24 | Alkermes Pharma Ireland Limited | Reduction de l'agregation a l'origine de paillettes dans des compositions a base d'un principe actif nanoparticulaire |
| KR101800036B1 (ko) | 2009-11-04 | 2017-11-22 | 메르크 파텐트 게엠베하 | 액정 매질용 화합물, 및 고주파 부품을 위한 그의 용도 |
| KR102303762B1 (ko) | 2017-06-14 | 2021-09-23 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| JP2021524505A (ja) * | 2018-05-19 | 2021-09-13 | ゲイリー ビンヤミン, | 発泡体製剤および身体への送達法 |
| CN114712316B (zh) * | 2020-12-18 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种难溶性药物组合物及制备方法 |
| US12083081B2 (en) * | 2021-04-29 | 2024-09-10 | Protara Therapeutics, Inc. | Sterile aqueous choline salt compositions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| US20060188566A1 (en) * | 2005-02-24 | 2006-08-24 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739303B2 (en) * | 1997-08-21 | 2001-10-11 | Florida State University | Method for the synthesis of taxanes |
| GB9820457D0 (en) * | 1998-09-18 | 1998-11-11 | Medlogic Global Corp | Methods for sterilizing cyanoacrylate compositions |
| US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US20020141966A1 (en) * | 2000-11-16 | 2002-10-03 | Wenbin Dang | Compositions for treatment of malignant effusions, and methods of making and using the same |
-
2008
- 2008-03-20 JP JP2009554749A patent/JP2010522207A/ja not_active Withdrawn
- 2008-03-20 EP EP08732593A patent/EP2139470A4/fr not_active Withdrawn
- 2008-03-20 WO PCT/US2008/057701 patent/WO2008118754A2/fr not_active Ceased
- 2008-03-20 CA CA002680106A patent/CA2680106A1/fr not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| US20060188566A1 (en) * | 2005-02-24 | 2006-08-24 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
Non-Patent Citations (1)
| Title |
|---|
| MERISKO-LIVERSIDGE E ET AL: "Nanosizing: A formulation approach for poorly-water-soluble compounds", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES FEBRUARY 2003 ELSEVIER NL, vol. 18, no. 2, February 2003 (2003-02-01), pages 113 - 120, XP002586752, DOI: 10.1016/S0928-0987(02)00251-8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010522207A (ja) | 2010-07-01 |
| CA2680106A1 (fr) | 2008-10-02 |
| EP2139470A2 (fr) | 2010-01-06 |
| WO2008118754A2 (fr) | 2008-10-02 |
| WO2008118754A3 (fr) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20200775A1 (no) | Fremgangsmåter og sammensetninger for behandling av kreft | |
| EP2139470A4 (fr) | Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés | |
| CY2020042I2 (el) | Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων | |
| CY2019010I1 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
| DK2473034T3 (da) | Frøbehandlingssammensætninger og fremgangsmåde | |
| CY2014026I2 (el) | Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας | |
| EP2331155A4 (fr) | Biocomposites et leurs procédés de fabrication | |
| EP2413693A4 (fr) | Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation | |
| PL2144998T3 (pl) | Sposoby i kompozycje dla żywych atenuowanych wirusów | |
| EP2214597A4 (fr) | Implants rachidiens et procédés | |
| DE602007008066D1 (de) | Polyethylenzusammensetzungen und daraus hergestelltes rohr | |
| FR2977139B1 (fr) | Implant inter-epineux et instrument d’implantation | |
| EP2506967A4 (fr) | Composition de nanoparticules et ses procédés de préparation | |
| EP2002263A4 (fr) | Compositions d'immunothérapie pour cancer et méthodes d'utilisation | |
| EP2400921A4 (fr) | Implants orthopédiques personnalisés et procédés associés | |
| EP2904094A4 (fr) | Compositions micronisées composées de greffons osseux et leurs procédés de fabrication et d'utilisation | |
| BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
| BRPI0812562A2 (pt) | composições terapêuticas anti-cd20 e métodos | |
| EP2230906A4 (fr) | Compositions d'anidulafungine nanoparticulaires et leurs procédés de fabrication | |
| EP2302664A4 (fr) | Appareil multi-colonnes d exposition par faisceau d électrons et appareil générateur de champ magnétique | |
| DK2154966T3 (da) | Benzimidazoler og farmaceutiske sammensætninger deraf | |
| EP2365978A4 (fr) | Compositions de lécithine et de plastifiant et procédés | |
| BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
| SMT201700084B (it) | Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20091020 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20091230 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61L 2/00 20060101AFI20100115BHEP Ipc: A61N 5/00 20060101ALI20100115BHEP Ipc: A61K 31/335 20060101ALI20100115BHEP |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/19 20060101ALI20100614BHEP Ipc: A61K 9/14 20060101ALI20100614BHEP Ipc: A61K 31/337 20060101AFI20100614BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20100629 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1140408 Country of ref document: HK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20120222 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120704 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1140408 Country of ref document: HK |